In conclusion, adjuvant CIK cell immunotherapy significantly prolongs RFS in early-stage HCC patients and reduces AFP and PIVKA-II levels in high-risk subgroups with elevated post-treatment markers. The gene discussed is AFP; the disease is hepatocellular carcinoma.